| GlaxoSmithKline AG - Boostrix Polio, Injektionssuspension | | 00681 | | 01 | | Boostrix Polio | | Injektionssuspension | | J07CA02 | | Diphtherie-Pertussis-Poliomyelitis-Tetanus | | 01.04.2004 | | |
| | Composition | | toxoidum diphtheriae ≥ 2 U.I., toxoidum tetani ≥ 20 U.I., toxoidum pertussis 8 µg, haemagglutininum filamentosum von Bordetella pertussis 8 µg, pertactinum von Bordetella pertussis 2.5 µg, virus poliomyelitis typus 1 inactivatus 40 U., virus poliomyelitis typus 2 inactivatus 8 U., virus poliomyelitis typus 3 inactivatus 32 U., natrii chloridum corresp. natrium 1.8 mg, aluminium 0.5 mg ut aluminii hydroxidum hydricum ad adsorptionem et aluminii phosphas, medium 199, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml, residui: neomycini sulfas, polymyxini B sulfas, polysorbatum 80, formaldehydum. | | Packungsbestandteile | | Principe actif |
|---|
| Vaccinum Diphtheriae Adsorbatum | | Vaccinum Pertussis Acell. Adsorbatum | | Vaccinum Poliomyelitidis Inactivatum (Salk typ I, II, III) | | Vaccinum Tetani Adsorbatum |
| | BAG: Principe actif | Concentr. |
|---|
| Toxoidum Diphtheriae | 2 UI | | Toxoidum Pertussis | 8 mcg | | Toxoidum Tetani | 20 UI | | Vaccinum Poliomyelitidis Inactivatum (Salk typ I, II, III) | 80 U |
|
| | numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 003 | | 24.86 | 43.45 | B | LS | Non | | 004 | 10 | DDP | DDP | B | | Non |
|
|
